PHOENIX – A wealthy Phoenix-area real estate developer and a business his sons control have been ordered to pay $171 million by a jury for a contested land deal.

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US, adding $11 billion in new spending as the industry prepares for potential sector-specific ...